These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Neurotransmitters in Alzheimer's disease]. Manzano-Palomo S; De la Morena-Vicente MA; Barquero MS Rev Neurol; 2006 Mar 16-31; 42(6):350-3. PubMed ID: 16575771 [TBL] [Abstract][Full Text] [Related]
3. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Lanari A; Amenta F; Silvestrelli G; Tomassoni D; Parnetti L Mech Ageing Dev; 2006 Feb; 127(2):158-65. PubMed ID: 16297434 [TBL] [Abstract][Full Text] [Related]
4. The interplay of neurotransmitters in Alzheimer's disease. Francis PT CNS Spectr; 2005 Nov; 10(11 Suppl 18):6-9. PubMed ID: 16273023 [TBL] [Abstract][Full Text] [Related]
5. [Neuromediators and memory. From research to therapy]. Zuber M; Guez D Ann Med Interne (Paris); 1989; 140(8):709-14. PubMed ID: 2576500 [No Abstract] [Full Text] [Related]
6. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713 [TBL] [Abstract][Full Text] [Related]
7. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! Tabet N Age Ageing; 2006 Jul; 35(4):336-8. PubMed ID: 16788077 [TBL] [Abstract][Full Text] [Related]
8. The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update. Khoury R; Grysman N; Gold J; Patel K; Grossberg GT Expert Opin Investig Drugs; 2018 Jun; 27(6):523-533. PubMed ID: 29848076 [TBL] [Abstract][Full Text] [Related]
11. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? Benzi G; Moretti A Eur J Pharmacol; 1998 Apr; 346(1):1-13. PubMed ID: 9617746 [TBL] [Abstract][Full Text] [Related]
13. The neurochemistry of Alzheimer's disease and senile dementia. Davies P Med Res Rev; 1983; 3(3):221-36. PubMed ID: 6136637 [TBL] [Abstract][Full Text] [Related]
14. Neurotransmitter Imbalance in the Brain and Alzheimer's Disease Pathology. Snowden SG; Ebshiana AA; Hye A; Pletnikova O; O'Brien R; Yang A; Troncoso J; Legido-Quigley C; Thambisetty M J Alzheimers Dis; 2019; 72(1):35-43. PubMed ID: 31561368 [TBL] [Abstract][Full Text] [Related]
15. [Pharmacological correction of Alzheimer's disease (review of the literature)]. Groppa SA Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(9):110-6. PubMed ID: 1686127 [No Abstract] [Full Text] [Related]
16. Biochemical pathology and treatment strategies in Alzheimer's disease: emphasis on the cholinergic system. Winblad B; Messamore E; O'Neill C; Cowburn R Acta Neurol Scand Suppl; 1993; 149():4-6. PubMed ID: 8128837 [TBL] [Abstract][Full Text] [Related]
17. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Francis PT; Ramírez MJ; Lai MK Neuropharmacology; 2010; 59(4-5):221-9. PubMed ID: 20156462 [TBL] [Abstract][Full Text] [Related]
18. Dementia: the neurochemical basis of putative transmitter orientated therapy. Court JA; Perry EK Pharmacol Ther; 1991 Dec; 52(3):423-43. PubMed ID: 1687928 [TBL] [Abstract][Full Text] [Related]
19. The neurochemistry of agitation in Alzheimer's disease: a systematic review. Liu KY; Stringer AE; Reeves SJ; Howard RJ Ageing Res Rev; 2018 May; 43():99-107. PubMed ID: 29524596 [TBL] [Abstract][Full Text] [Related]
20. Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's Disease. Werner FM; Covenas R Curr Pharm Des; 2016; 22(14):2064-71. PubMed ID: 26818863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]